Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Blue rubber bleb nevus syndrome medical therapy
Introduction
Overview
Overview
The mainstay of treatment for blue rubber bleb nevus syndrome is interferon-beta, octreotide, iron supplementation and blood transfusions.
Medical Therapy
Medical Therapy
- Pharmacologic medical therapies for blue rubber bleb nevus syndrome include:[1][2][3][4][5]
- Preferred regimen (1): Interferon-beta, 1.2 mg/m2/day for 2 month
- Preferred regimen (2): Octreotide, 5.7 microg/kg subcutaneously twice daily for 4 weeks[6]
- Preferred regimen (3): Sirolimus,1.2 mg/m2/day for 2 months [7]
- Preferred regimen (4): Iron supplementation
- Preferred regimen (5): Blood transfusions
- Preferred regimen (6): Corticosteroids
- Preferred regimen (7): Propranolol, 40 mg twice daily; titrate weekly as needed based on patient response
- Preferred regimen (8): Thalidomide
References
References
- ↑ Agnese M, Cipolletta L, Bianco MA, Quitadamo P, Miele E, Staiano A (April 2010). “Blue rubber bleb nevus syndrome”. Acta Paediatr. 99 (4): 632–5. doi:10.1111/j.1651-2227.2009.01608.x. PMID 19958301.
- ↑ Jain A, Kar P, Chander R, Khandpur S, Jain S, Prabhash K, Gangwal P (1998). “Blue rubber bleb nevus syndrome: a cause of gastrointestinal hemorrhage”. Indian J Gastroenterol. 17 (4): 153–4. PMID 9795507.
- ↑ Jin, Xue-Li (2014). “Blue rubber bleb nevus syndrome: A case report and literature review”. World Journal of Gastroenterology. 20 (45): 17254. doi:10.3748/wjg.v20.i45.17254. ISSN 1007-9327.
- ↑ Boente, Maria del C.; Cordisco, Maria R.; Frontini, Maria del V.; Asial, Raul A. (1999). “Blue Rubber Bleb Nevus (Bean Syndrome): Evolution of Four Cases and Clinical Response to Pharmacologic Agents”. Pediatric Dermatology. 16 (3): 222–227. doi:10.1046/j.1525-1470.1999.00065.x. ISSN 0736-8046.
- ↑ Ogu, Ugochi O.; Abusin, Ghada; Abu-Arja, Rolla F.; Staber, Janice M. (2018). “Successful Management of Blue Rubber Bleb Nevus Syndrome (BRBNS) with Sirolimus”. Case Reports in Pediatrics. 2018: 1–5. doi:10.1155/2018/7654278. ISSN 2090-6803.
- ↑ Gonzalez D, Elizondo BJ, Haslag S, Buchanan G, Burdick JS, Guzzetta PC, Hicks BA, Andersen JM (August 2001). “Chronic subcutaneous octreotide decreases gastrointestinal blood loss in blue rubber-bleb nevus syndrome”. J. Pediatr. Gastroenterol. Nutr. 33 (2): 183–8. PMID 11568521.
- ↑ Ãœnlüsoy Aksu A, Sari S, EÄŸritaÅŸ Gürkan Ö, Dalgiç B (March 2017). “Favorable Response to Sirolimus in a Child With Blue Rubber Bleb Nevus Syndrome in the Gastrointestinal Tract”. J. Pediatr. Hematol. Oncol. 39 (2): 147–149. doi:10.1097/MPH.0000000000000681. PMID 27820137.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Vamsikrishna Gunnam M.B.B.S [2]